Moncton, New Brunswick — December 31, 2025 — Leads & Copy —
Organigram Global Inc., Canada’s #1 cannabis company by market share, has announced the expansion of its innovation investment in Phylos Bioscience Inc., securing its position as a leader in seed-based cannabis genetics. Through an amended loan and product agreement, Organigram gains priority access to Phylos’ autoflower genetics pipeline, including preferential economic terms and long-term rights in its international markets. This establishes a foundation for product differentiation and growth in recreational and medical markets.
According to Borna Zlamalik, SVP Innovation & International R&D at Organigram, seed-based cultivation has become a key advantage of Organigram’s cultivation strategy, giving the company consistency, scalability, and economic benefit. The follow-on investment in Phylos secures the portfolio breadth of next-generation cultivars required to meet the needs of Organigram’s consumers and patients.
Under the amended product agreement, Organigram receives five-year exclusivity on its chosen autoflower cultivars across international markets, including Canada, Australia, the UK, Germany, and Israel, with the ability to add new exclusive territories as it expands globally. Annual portfolio reviews will maintain exclusivity only for commercially relevant cultivars, maximizing flexibility and strengthening Organigram’s international product differentiation strategy as it enters high-value medical markets.
Under the terms of the amended loan agreement, Organigram will consolidate its existing investment with a new US$3 million advance, resulting in a combined total loan principal of US$10 million. The loan matures on May 25, 2028, and is subject to conversion or other resolution mechanisms under the amended agreement.
Ralph Risch, CEO of Phylos, said that Organigram saw early that the next phase of cannabis production would be driven by scientifically bred genetics. He added that their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.
Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets.
Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O’ Buds, SHRED, Monjour, Tremblant, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class extraction capabilities and is optimized for formulation refinement, post-processing of minor cannabinoids, and infused pre-roll production. The facility in London will be optimized for labeling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations.
Phylos is a cannabis genetics company focused on producing scientifically bred genetics that enable the highest quality cannabis to be grown at scale in a cost-effective way. Phylos supports commercial-scale cultivation with the industry’s first Production-Ready Seed™: premium, phenotypically stable, fully feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigour, and yield.
Borna Zlamalik, SVP Innovation & International R&D at Organigram
Source: Organigram Global Inc.
